
    
      This is a multi-centric prospective non randomized open labeled study performed on a cohort
      of patients with inoperable recurrent and/or metastatic HNSCC who will be treated, with a
      first line treatment based on an anti-Human Epidermal Growth Factor Receptor (HER), the
      Cetuximab.
    
  